The adverse effects of TP53 alterations on MDS clinical phenotypes and outcome (more aggressive disease and poorer response to treatment) have been widely documented; the role of TP53 mutations as predictors of poor OS in MDS patients has been uniformly described, independently of established risk factors [97,121,122,123,124,125]. This evidence concerns the gene TP53 and myelodysplastic syndrome.